Eton Pharmaceuticals, Inc.
NASDAQ:ETON · NASDAQ Global Market
-$0.46 today
Vol 0.58M · Avg 0.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.6%
avg -64.3%
ROIC
0.1%
avg -44.0%
ROA
-5.0%
avg -40.9%
Analysis
ROIC is currently the strongest return metric at 0.1% versus its period average of -44.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean E. Brynjelsen | President, Chief Executive Officer & Director | $1.08M | — | 54 | $833,694.00 | 3.04% |
James R. Gruber | Consultant | $740,508.00 | — | 54 | $213,420.00 | 0.78% |
David Krempa | Chief Business Officer | $737,185.00 | — | 37 | $118,406.00 | 0.43% |
Ipek Erdogan-Trinkaus | Chief Commercial Officer | $575,292.00 | — | 44 | $149,734.00 | 0.55% |
Danka Radosavljevic | Executive Vice President of Operations | — | — | — | — | — |
Judith Matthews | Chief Financial Officer | — | — | 56 | $0.00 | <0.01% |
Scott Grossenbach | Senior Vice President of Sales Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$9.35M
Net Sentiment
$9.35M
Net selling
Most Active
Krempa David
5 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $9.35M over the last 12 months. That adds up to net selling of $9.35M. Krempa David was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +39.7% (9yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +39.7% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$881.73M
Omeros Corporation
NASDAQ:OMER
$732.44M
Monopar Therapeutics Inc.
NASDAQ:MNPR
$445.49M
Ocugen, Inc.
NASDAQ:OCGN
$428.23M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$305.39M
Bicycle Therapeutics plc
NASDAQ:BCYC
$277.58M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$270.51M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$188.85M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
Who manages ETON?
Eton Pharmaceuticals, Inc. (ETON) lists 7 active executives. The top listed executive is Danka Radosavljevic, Executive Vice President of Operations.
Are ETON insiders buying or selling?
Recent insider activity shows net selling of $7.29M.
Explore More
Continue the stock analysis
Jump to another research area for this company.